Clearstone and Mitsubishi Announce Preferred Provider Relationship to Provide Greater Access to Central Lab Services Throughout Asia-Pacific
Clearstone Central Laboratories
announced that it has entered into a partnership with
Mitsubishi Chemical Medience Corporation
(Mitsubishi). This preferred provider relationship provides clients of both companies with access to CAP-accredited laboratories for safety and specialty testing services throughout the Asia-Pacific region and around the world. The cross-collaboration opens access for Mitsubishi clients not only to Clearstone’s lab in China but to its global laboratory network, and creates a new solution for Clearstone clients to access Mitsubishi’s lab network in Japan.
“We are very pleased to announce the Mitsubishi partnership given the value and opportunities it creates for our clients”, said Clearstone CEO Lewis Cameron. “Mitsubishi is well established in Japan, and this agreement extends their reach and capabilities to other strategic markets, including our renowned laboratory in China. We look forward to aligning our operational and business development activities, as well as providing our clients with access to the Japanese market”.
This announcement follows a collaborative agreement that Clearstone signed with the Esoterix Clinical Trials Services division of LabCorp last year.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
